Anti-SEMA4D antibody treatment prevents bone loss and encourages bone development in a mouse model of postmenopausal osteoporosis without influencing osteoclast-mediated bone resorption, indicating that SEMA4D may be a possible pharmacological object for osteoporosis and other decreased bone density diseases (Pederson et al., 2008). Here, SEMA4D is linked to postmenopausal osteoporosis.